

Day One, 6th March 2017**07:15 Registration & Coffee****08:10 Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates Ltd.****Bio-Pharma Industry Overview for 2017: Challenges and Opportunities Panel - Room Panorama A**

Chaired by:

Stephanie Léouzon, Partner and Head of Torrey Partners Europe, Torrey Partners (Europe) LLP

Panelists:

08:20 Adam Kostyál, Senior Vice President, NASDAQ OMX

Jim Philips, CEO, Midatech Pharma PLC

Mark Altmeyer, President and Chief Commercial Officer, Axovant Sciences Ltd.

Sarah Holland, VP, BD&L Business Partner, GEM Business Unit, Sanofi

Sascha Alilovic, VP, Head of Corporate Finance & Corporate Development, MorphoSys AG

09:05 "Drug Chess - Planning a Few Moves Ahead of the Competition" by Peter Kolchinsky, Portfolio Manager and Managing Director, RA Capital - Room Panorama A**Private Equity & VC Panel - Room Panorama A**

Co-Chaired by:

Markus Goebel, Managing Director, Novartis Venture Fund

Markus Hosang, General Partner, BioMedPartners AG

Panelists:

09:30 Arthur Franken, Partner, Gilde Healthcare Partners

Eric de La Fortelle, Venture Partner, Seventure Partners

Lionel Carnot, Managing Director, Bay City Capital

Maciek Drozd, Principal, Venture Investments, London Innovation Center, Johnson & Johnson Innovation

Paul Hermant, Partner, Bird & Bird LLP

Thierry Chignon, Senior Partner, Merieux Developpement

10:30 Coffee Break

Sponsored by:



Supported by:



10:45 French BioPharma Investment Panel - Room Panorama A
Co-Chaired by:
 Cedric Moreau, Managing Director - Head of Healthcare, Oddo & Cie
 Christophe Bourrilly, Managing Director, KRONOS ADVISORS
Panelists:
 Aaron Bensimon, CEO, Genomic Vision
 Chris Maggos, Managing Director, Europe, LifeSci Advisors
 Marc Le Bozec, Fund Manager, Pluvalca Biotech
 Remi Droller, Managing Partner, Kurma Partners
 Thibaut Roulon, Investment Director, Life Sciences, Bpifrance

10:45 Vaccines & Infectious Diseases Panel - Room Panorama C
Chaired by:
 Florian Schödel, Owner, Philimmune, LLC
Panelists:
 Bill Hearl, President & CEO, Immunomic Therapeutics, Inc.
 Geoff Dow, CEO, 60 Degrees Pharmaceuticals, LLC
 Nicholas Benedict, CEO, Allegra Therapeutics GmbH
 Pierre Courteille, CCO and VP BD, ABIVAX
 Wouter Latour, CEO, Vaxart, Inc.

Presentation Track A - Room Berne
Moderated by: Sven Rohmann, Suenos Advisors Est.

11:30 Platform & Enabling Technologies Panel 1 - Room Panorama A
Chaired by:
 Peter Dudek, Principal, Wellington Partners
Panelists:
 Alexandra Richardson, Head of BD, Clayton Biotechnologies, Inc.
 Cedric Verwerken, CEO, Confo Therapeutics
 Martin Welschof, CEO, Opona Therapeutics Ltd.
 Michael Motz, CEO, MAB Biopharmaceuticals
 Nanna Luneborg, Principal, Novo Ventures
 Yochi Slonim, Co-Founder & CEO, Anima Biotech Ltd.

11:30 CNS Panel 1 - BD&L - Room Panorama C
Chaired by:
 Jennifer Laird, Senior Director, Search & Evaluation, Eli Lilly & Company
Panelists:
 Anja König, Managing Director, Novartis Venture Fund
 François Conquet, CEO, Prexton Therapeutics
 Laura Corradini, Deputy Global Head, CNS BD&L, Boehringer Ingelheim GmbH
 Sofia Ioannidou, Investment Director, Life Sciences, Edmond de Rothschild Investment Partners

10:45 OSE Immunotherapeutics - [OSE: EN]

11:00 Opona Therapeutics Ltd.

11:15 Oxford BioMedica PLC - [LON: OXB]

11:30 ThromboGenics NV - [EBR: THR]

12:15 Platform & Enabling Technologies Panel 2 - Gene Editing & Cell Therapy Room Panorama A
Co-Chaired by:
 Alain Vertes, Director EU Section, Alliance for Regenerative Medicine
 Katya Smirnyagina, Partner, Capricorn Venture Partners NV
Panelists:
 Daniel Gau, Head of BD, COO, Unicyte AG
 David Venables, CEO, Synpromics Ltd.
 Dirk Reyn, CEO, eTheRNA immunotherapies NV
 Stephane Boissel, CEO, TxCell SA

12:15 CNS Panel 2 - Advanced Therapeutics - Room Panorama C
Co-Chaired by:
 Laurence Barker, Dementia Discovery Fund CBO, SV Life Sciences
 Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners
Panelists:
 Brad Margus, CEO, Cerevance
 Kjell Stenberg, CEO, Cyxone AB
 Laurent Nguyen, CEO, Sensorion SA
 Tim Dyer, CEO, Addex Therapeutics Ltd.

11:45 Cyxone AB

12:00 SOM Biotech

12:15 Oncomatryx Biopharma, S.L.

13:00 Networking Lunch - served in Registration Room and Horizon Restaurant

Space for Notes:

Presentation Track B - Room Panorama C
Moderated by: Bob Pooler, valuationLAB AG

14:00 TxCell SA - [EPA: TXCL]

14:15 Genomic Vision - [EPA: GV]

14:30 Anima Biotech Ltd.

14:45 Synaffix BV

15:00 60 Degrees Pharmaceuticals, LLC

15:15 MyCartis

15:30 Eligo Bioscience

15:45 eTheRNA immunotherapies NV

16:00 Coffee Break

Presentation Track C - Room Berne
Moderated by: Hans Herklots, Capricorn One

14:00 Curetis N.V. - [CURE: NA]

14:10 NetScientific PLC - [LON: NSCI]

14:20 TaiwanJ Pharmaceuticals - [6549: TT]

14:30 MAB Biopharmaceuticals

14:40 Mymetics Corporation - [OTCMKTS: MYMX]

14:50 Medicortex Finland Oy

15:00 Allecra Therapeutics GmbH

15:10 Orbit Discovery

15:20 DATA 4 ACTIONS, Inc. – TOWWERS Program

15:30 Greenbone Ortho SRL

15:40 Lytix Biopharma AS

15:50 Immunic AG

Space for Notes: _____

16:15 Autoimmune & Inflammatory Diseases Panel - Room Panorama A
Co-Chaired by:
Jasper Bos, VP and Head of Healthcare Fund, Merck Ventures B.V.
Markus Kalousek, Global BD&L S&E Franchise Head (I&D), Novartis Pharma AG
Panelists:
Adam Houghton, Senior Director & Head, Immunology Search and Evaluation, AbbVie, Inc.
Daniel Vitt, CEO, Immunic AG
Fabian Büller, Director, New Ventures, Johnson & Johnson Innovation, LLC
Josep M. Casanovas, Head of Immuno-Dermatology, External Innovation & Licensing, Almirall S.A.
Thomas Hanke, EVP Inflammation and Immunology, Evotec International GmbH

17:00 Diagnostics & Biomarkers Panel - Room Panorama A
Chaired by:
Beat Merz, Managing Director, Rockport Venture Partners
Panelists:
Claire Huguet, Head of Biomarker Services, Randox Laboratories Ltd.
Joris Schuurmans, CEO, MyCartis
Miro Venturi, Global Head - Diagnostics Biomarkers, F. Hoffmann-La Roche Ltd.
Oliver Schacht, CEO, Curetis N.V.
Tom Gibbs, Director Investments, Alliances & Licensing, Debiopharm Innovation Fund

Presentation Track E - Room Panorama C
Moderated by: Jørgen Thorball, XOventure GmbH

- 16:15** Acesion Pharma ApS
- 16:25** Acticor Biotech SAS
- 16:35** CardioRenal SAS
- 16:45** InterAx Biotech AG
- 16:55** Strekin AG
- 17:05** Origenis GmbH
- 17:15** Timmune Biotech, Inc.
- 17:25** 20Med Therapeutics B.V.

Presentation Track F - Room Berne
Moderated by: Subhasis Roy, Sirius Healthcare Partners

- 16:15** ABIVAX - [EPA: ABVX]
- 16:30** Vaxart, Inc.
- 16:45** Immunomic Therapeutics, Inc.
- 17:00** Hookipa Biotech AG
- 17:15** Vaximm AG
- 17:30** Invecitys SA

17:45 Networking Reception
20:00 End of Reception & Day One

Sponsored by:



Supported by:



Day Two, 7th March 2017

Wi-Fi Access Information
Network Name: **Hilton Meetings**
Access Code: **zrhh1703**

08:00 Registration & Coffee

Bio-Pharma DealMaking Outlook for 2017 Panel - Room Panorama A
Chaired by:
Fintan Walton, CEO, PharmaVentures Ltd.
Panelists:
Alexander Breidenbach, Director, Global BD Neuroscience, F. Hoffmann - La Roche Ltd.
08:30 Ben Thorner, Senior Vice President and Head of BD&L, MSD
Emilio Erazo-Fischer, Associate Director of Global Oncology BD&L, Boehringer Ingelheim GmbH
Frank Grams, VP, Global Head R&D Alliance Management, Sanofi
Nathalie ter Wengel, European Head External R&D and Innovation, Pfizer, Inc.
Olivier Crauk, Director Corporate BD, Ipsen
Patrick Benz, Senior Director Alliance Management, Johnson & Johnson

Oncology DealMaking Panel - Room Panorama A
Co-Chaired by:
David Colpman, Director, Colpman Consulting Ltd.
Esteban Pombo-Villar, Independent Consultant
Panelists:
09:15 Allison Jaynes-Ellis, CEO, Avillion LLP
Catherine Pickering, Head of Oncology & Immuno-Oncology Licensing, Merck KGaA
Jason Slingsby, Head of BD, Oxford BioMedica PLC
John Haurum, CEO, F-Star Biotechnology Ltd.
Laurent Audoly, Managing Partner and Founder, Pierre Fabre Fund for Innovation
Stephen Sands, BD&L Director, F. Hoffmann-La Roche Ltd.
Thilo Schroeder, Partner, Nextech Invest Ltd.

10:15 "VC Investment Decisions – Market Access Considerations and Important Value Driver" by Thomas Hasmann, VP Market Access, HighPoint Solutions - Room Panorama A

10:35 Coffee Break

Sponsored by:



Supported by:



BaseLaunch Presentation - Room Panorama A

Speaker:

Alethia De Leon, Managing Director, BaseLaunch

14:00 Q&A with:

Anja König, Managing Director, Novartis Venture Fund

Fabian Büller, Director, New Ventures, Johnson & Johnson Innovation, LLC

Nathalie ter Wengel, European Head External R&D and Innovation, Pfizer, Inc.

Rising Stars: Start-Up Showcase, Single Track of 3 minute presentations - Room Panorama A

Moderated by:

Ulrich Mühlner, Founder & Managing Director, GrowthCube Partners, LLC

Rao Movva, Novartis Distinguished Scientist (retired) & Currently Independent Pharma and Biotech Advisor

Presenting Order:

14:20

- | | | | |
|----|--|-----|------------------------------|
| 1. | ABBA Therapeutics | 8. | Skin-Deep Technologies AG |
| 2. | Elthera AG | 9. | Cytomatics |
| 3. | MyeloPro Diagnostics and Research GmbH | 10. | Lumigbo |
| 4. | SUINCol | 11. | Microsleep Diagnostic Device |
| 5. | PanCryos | 12. | Intento |
| 6. | Anjarium Biosciences AG | 13. | E-Medicus |
| 7. | PhytoSwiss Pharma | 14. | Medicinisto AG |

Seed Companies Investor Roundtable - Room Panorama A

Co-Chaired by:

Christina Trojel, Senior Investment Associate, Novo Seeds

Hakan Goker, Senior Investment Director, Merck Ventures B.V.

15:30

Panelists:

Dirk Kersten, Managing Director, INKEF Capital BV

Emmanuel Elalouf, Partner, Cukierman Life Sciences


Richard Seabrook, Senior Advisor, Wellcome Trust

Ulrich Mühlner, Founder & Managing Director, GrowthCube Partners, LLC

16:00 Last Chance to Network & Farewell Drinks

16:40 End of the 10th ELSCEO Forum & Exhibition

Sponsored by:



Supported by:

